2028 Compounding Process Improvement 
Putting Patients First Blog
JUNE 26, 2025
Inclusion of Part B Drugs: Scope, Challenges, and Opportunities The addition of provider-administered therapies covered under Medicare Part B to the IPAY 2028 cycle introduces a fundamentally different reimbursement and care delivery context than that of pharmacy-dispensed Part D drugs.
Syner-G
SEPTEMBER 15, 2023
Structure-based drug design has evolved, facilitating the exploration of novel chemical probes and lead compound potency, and molecular docking utilizes target structures to predict interactions and offers simplicity and speed. billion by 2028. Both processes are evolving to enhance product development and output.
Expert insights. Personalized for you.
52 
Let's personalize your content